Extended Release OROS® Paliperidone
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions
Schizophrenia
Phase 3
A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
CompletedNCT00645307
Start: 2004-05-31End: 2006-08-31Updated: 2011-06-08
A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
CompletedNCT00650793
Start: 2004-03-31End: 2006-02-28Updated: 2011-06-08